Journal of Clinical Oncology
Articles in this Issue
Real-world utility of Histotype Px colorectal as a prognostic and potentially predictive biomarker.
215 Background: The decision to offer adjuvant chemotherapy (ACT) for patients with high-risk stage II and stage III colon...
A phase II study of stereotactic body radiotherapy and focal adhesion kinase inhibitor in advanced pancreatic adenocarcinoma.
740 Background: There are limited treatment options for pts with borderline resectable (BRPC) and locally advanced (LAPC)...
A phase 2 randomized, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in patients with malignant disease.
TPS855 Background: Chemotherapy-induced nausea and vomiting (CINV) remains an important concern for patients (pts) receivi...
Use of liquid biomarkers to track fibrotic changes in pancreatic cancer patients treated with combined immunotherapy and radiotherapy (CheckPAC).
762 Background: Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, with low treatment response and &l...
Clinical impact of chemotherapy and immune checkpoint inhibitor treatment in high-risk stage II and III colorectal cancer patients with dMMR/MSI-H and/or TMB-H status.
177 Background: The phase 3 ATOMIC trial (NCT02912559) demonstrated the addition of an immune checkpoint inhibitor (ICI) t...
Neoadjuvant chemotherapy for colorectal cancer with synchronous and exclusive peritoneal metastasis: A comprehensive retrospective cohort study.
169 Background: Colorectal cancer (CRC) with synchronous and exclusive peritoneal metastases (PM) is rare and associated w...
The Liver Cancer and Frailty in Elderly (LIFE) study: Longitudinal functional status analysis in patients with advanced hepatocellular carcinoma (HCC) and prognostication.
521 Background: The incidence of HCC has tripled over recent decades, with a disproportionately higher burden among older...
Gut microbiota perturbations in response to SARS-CoV-2 and survival outcomes in patients with cancer.
178 Background: The gut microbiota plays a critical role in immune function, but in diseases such as cancer, dysbiosis may...
Reproducibility and clinical concordance of a tumor-informed MRD assay in patients with resected colorectal cancer from the DYNAMIC trials.
26 Background: Haystack MRD is a highly accurate, tumor-informed ctDNA assay designed for minimal residual disease (MRD) d...
Use of liquid biopsy molecular profiling among Native American patients with pancreatic ductal adenocarcinoma: A retrospective study from a minority-serving cancer center (2017-2022).
777 Background: Pancreatic ductal adenocarcinoma (PDAC) molecular profiling guides treatment selection, yet liquid biopsy...
A simple ABC score for prognosis stratification and treatment selection in advanced hepatocellular carcinoma.
511 Background: Atezolizumab plus bevacizumab (A+B) is widely used as a standard first-line therapy for advanced hepatocel...
Results from the randomized phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
653 Background: Elraglusib (9-ING-41), a novel small molecule inhibitor of GSK-3ß, has a multimodal mechanism of action th...
Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT as first-line treatment for locally advanced (LA), unresectable esophageal squamous cell carcinoma (ESCC): PD-L1 tumor area positivity (TAP) score ≥1% subgroup analysis of RATIONALE-306.
381 Background: In RATIONALE-306 (NCT03783442), patients (pts) with LA unresectable or metastatic ESCC who received TIS (i...
External validation of MAGIC-D in Taiwanese patients with advanced biliary tract cancer receiving durvalumab and chemotherapy.
502 Background: The TOPAZ-1 trial established gemcitabine–cisplatin–durvalumab (GCD) as first-line therapy for advanced bi...
Clinical significance of a "false positive" stool multi-target DNA test.
803 Background: It has been suggested with limited data that a "false positive" result on a stool multi-target DNA (mtDNA)...
Effect of chemoimmunotherapy on survival in stage II-IV gastric adenocarcinoma: An NCDB retrospective study.
415 Background: Gastric adenocarcinoma remains a leading cause of cancer-related deaths worldwide. Surgery with curative i...
A phase 3, randomized, double-blind, placebo-controlled study of lecithinized superoxide dismutase (PC-SOD) for the prevention of chemotherapy-induced peripheral neuropathy in patients with colorectal cancer receiving adjuvant mFOLFOX6 therapy (PROSPER study).
TPS257 Background: Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Oxalip...
Rethinking dogma: Association between radiation dose and pathologic outcomes or survival in patients receiving neoadjuvant radiotherapy for pancreatic cancer.
716 Background: Controversy endures regarding the role of radiotherapy (RT) in operable pancreatic ductal adenocarcinoma (...
Real-world outcomes of trifluridine/tipiracil ± bevacizumab in refractory metastatic colorectal cancer: A SUNLIGHT validation study.
81 Background: The SUNLIGHT trial (2023) demonstrated improved overall survival (OS) with trifluridine/tipiracil (TAS-102)...
Immunomodulatory effects of lenvatinib targeting immunosuppressive macrophages in combination with transarterial embolization in a rat hepatocellular carcinoma model.
585 Background: Combination strategies of transarterial chemoembolization (TACE) and systemic therapy have clinically gain...
ONC201 for chemoprevention of colorectal cancer.
TPS246 Background: Dordaviprone (ONC201) is an oral small molecule that antagonizes dopamine receptor D2/3 and agonizes th...
Exposure-response analyses from a randomized dose optimization study of telisotuzumab adizutecan (Temab-A) in combination with bevacizumab in patients with metastatic colorectal cancer (mCRC).
132 Background: Telisotuzumab adizutecan (Temab-A) is an antibody-drug conjugate (ADC) consisting of a c-Met targeting ant...
The relationship between the diagnostic interval length and survival in colon cancer: The role of diagnoses in the emergency department.
47 Background: The diagnostic interval, defined as the time from first cancer-related healthcare encounter to cancer diagn...
Targeting MAO B: A novel gut–brain axis link in colorectal cancer progression.
231 Background: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with recurrence and metastasi...
Phase I trial of efficacy and safety of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy, for gastroesophageal cancers.
398 Background: Advanced gastric and gastroesophageal junction (GC/GEJ) cancers are highly aggressive with limited late-li...